Current stock page

Stock Analysis

Ascendis Pharma A/S (ASND) Stock Analysis

Ascendis Pharma A/S (ASND) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

ASND Stock Analysis Summary

Ascendis Pharma A/S (ASND) currently has an AIQ Score of 72/100, indicating a bullish setup. Momentum is the strongest factor at 75/100. Value is the weakest current factor at 66/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

ASND at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$275.39
AIQ Score72/100
Overall ViewBullish
Technical Analysis ConsensusStrong Buy
Market Cap$18.92B
P/E Ratio (TTM)17.57
Forward P/E—
EPS (Q3 FY2026)$1.11
Revenue (Q3 FY2026)$367.46M
Dividend Yield (TTM)0.00%
Beta0.4
Volume826.1K
52-week range$188.07-$282.15
RSI 1474.7
50-Day SMA$242.67
200-Day SMA$239.85
Analyst Price Target$311.67
Next EarningsFeb 10, 2027
As of Nov 13, 2026 · Market close

ASNDAscendis Pharma A/S

Healthcare / Biotechnology

Leader

Strong Relative Position

BullishEdge 9/10
$275.39+$8.32 (+3.12%)

Latest quote

  • Momentum
    75
  • Value
    66
  • Quality
    71
  • Risk resilience
    72
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

ASND Stock Analysis Summary

Ascendis Pharma A/S (ASND) currently has an AIQ Score of 72/100, indicating a bullish setup. Momentum is the strongest factor at 75/100. Value is the weakest current factor at 66/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Bullish

In a bullish regime, ASND has AIQ Score of 72/100 with Momentum base of 75/100 and fading Value at 66/100. Wait for component alignment before adding exposure.

Healthcare · 3.12% stock move · ASND classified in Biotechnology.

Current Evidence

BullishASND is in a bullish AIQ regime; Momentum is the strongest visible factor at 75/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is ASND Bullish or Bearish Right Now?

ASND currently has a bullish overall setup. Momentum is the strongest factor at 75/100, while Value is weakest at 66/100. The current evidence suggests a constructive setup.

Bull Case
  • - Quality is supportive at 71/100.
  • - Momentum is constructive at 75/100.
  • - Risk Resilience is supportive at 72/100.
  • - Price is +13.48% above its 50-day SMA.
  • - Analyst target implies +13.17% upside from the latest quote.
Bear Case
  • - No strong bearish evidence is available in the current snapshot.

Current Consensus

ASND's Technical Analysis Consensus is currently Strong Buy, with 38 buy, 2 neutral, and 6 sell votes. ASND's 14-day RSI is 74.7, which places the stock in an overbought momentum range. ASND's beta is 0.4, indicating lower market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in ASND?

The largest recent change in ASND is Momentum moving up by 4.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.

AIQ Score
+3.0
Momentum
+4.0
Quality
+2.0
Risk
+0.0

What Would Change the ASND Outlook?

The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

ASND Decision Framework

Public evidence layers, setup checks, and risk context for Ascendis Pharma A/S.

Ascendis Pharma A/S (ASND) Stock Analysis

Ascendis Pharma A/S has an AIQ Score of 72/100 in a Bullish regime. Momentum is strongest at 75/100. Beta is 0.4, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextASND is in a Bullish AIQ regime with score 72/100.
Signal ConflictThe primary conflict is that momentum leads at 75/100 while value lags at 66/100.
Factor EvidenceMomentum 75/100 · Value 66/100 · Quality 71/100 · Risk 72/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Momentum is the strongest factor at 75/100.

TimingPass

Momentum is 75/100 and RSI (14) is 74.7.

Regime fitPass

ASND is in a Bullish regime at 72/100.

Risk controlPass

Risk factor is 72/100 with beta 0.4 and annual volatility 38.55%.

ConflictPass

Current conflict: momentum leads at 75/100 while value lags at 66/100.

AIQ Score
72/100
Price
$275.39
Beta
0.4
RSI (14)
74.7

ASND Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

ASND Fundamentals

ASND valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$367.46M
Net income
$73.53M
Free cash flow
$182.07M
View full ASND fundamental analysis

ASND Technical Analysis

ASND technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Buy
RSI 14
74.7
Price vs SMA-50
+13.48%
View full ASND technical analysis

ASND Stock Catalysts

Track ASND earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 10, 2027
Analyst target
$311.67
News items
5
View ASND earnings and stock catalysts

ASND Dividend Analysis

ASND dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View ASND dividend history and analysis

ASND Financial Data

ASND revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$367.46M
EPS
$1.11
Periods
8
View ASND financials

ASND Risk Analysis

ASND volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
0.4
Risk score
72/100
1Y volatility
38.55%
View ASND risk analysis

ASND Stock News

ASND stock news, market tone, recent headlines, and catalyst context.

News items
5
Updated
Nov 15, 2026
Sentiment
—
Read ASND stock news

ASND vs Biotechnology Peers

Current peer cohort: ASND · AUPH · AVBP · AXSM · BBIO. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
ASND
Current stock
72/10066/10075/10072/1000.8438.55%Current
AUPH
Aurinia Pharmaceuticals Inc.
75/10084/10073/10068/1000.1635.52%ASND vs AUPH
AVBP
ArriVent BioPharma, Inc.
35/100—23/10032/100-0.0881.51%ASND vs AVBP
AXSM
Axsome Therapeutics, Inc.
47/10065/10024/10057/1000.245.79%ASND vs AXSM
BBIO
BridgeBio Pharma, Inc.
64/10055/10069/10062/1000.5544.14%ASND vs BBIO
Pairwise Compare links: AUPH · AVBP · AXSM · BBIOASND vs AUPHASND vs AVBPASND vs AXSMASND vs BBIOCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a ASND stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for ASND: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
17.57
As of Nov 13, 2026
Revenue growth
72.01%
Gross margin
90.61%
Current debt / equity
0.3
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$367.46M
Quarter net income
$73.53M
Quarter free cash flow
$182.07M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bullish
Momentum
Bullish
RSI 14
74.7
MACD
7.75

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
72/100
Beta
0.4
Annual volatility
38.55%
Max drawdown
-19.66%

ASND Stock FAQ

What is ASND stock price today?

Ascendis Pharma A/S's current stock price is $275.39. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is ASND bullish or bearish right now?

ASND's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is ASND's market cap?

ASND's market cap is $18.92B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is ASND's current P/E ratio?

ASND's current P/E ratio is 17.57 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is ASND's RSI?

ASND's 14-day RSI is 74.7 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is ASND above its 50-day and 200-day moving averages?

ASND is 13.48% from its 50-day SMA and 14.82% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is ASND's next earnings date?

ASND's next earnings date is currently listed as Feb 10, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does ASND pay a dividend?

ASND's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.